GO
| HSI1 | 26,705.94 | +138.82 | 85.00B |
| HSCEI1 | 9,070.32 | +37.61 | 27.45B |
| Back Zoom + Zoom - Block Traded | |
|
2026-02-13 15:04:46 MEDBOT-B (02252.HK)'s core product, Toumai, has recorded a total order of over 200 units, implying an addition of approx. 20 orders since late January 2026, JPMorgan published a research report saying. This continues the strong momentum from October 2025 to January 2026, alleviating some market concerns about its sustainability. The coverage has expanded to over 50 countries and regions (compared to over 40 by the end of December 2025), with more than five units ordered in 12 markets, primarily led by emerging markets such as India and Brazil, while developed markets like Spain and Australia also achieved accelerated breakthroughs. The broker believed that this achievement establishes MEDBOT-B as a leading domestic enterprise in China, allowing it to benefit from the trend of import substitution. Therefore, JPMorgan rated MEDBOT-B at Overweight, with a target price of $41. ~ AASTOCKS Financial News Website: www.aastocks.com | |